紫茜合剂治疗慢性原发免疫性血小板减少症的临床观察

Clinical Observation on Ziqian Compound for Chronic Primary Immune Thrombocytopenia

目的:观察紫茜合剂治疗慢性原发免疫性血小板减少症的临床疗效。方法:将70例符合纳入标准的慢性ITP患者随机分为治疗组(紫茜合剂+达那唑)35例和对照组(单用达那唑)35例,两组疗程均为6个月。观察两组患者治疗后血小板计数变化情况。结果:治疗组临床总有效率(65.71%)优于对照组(48.57%)(P<0.05)。治疗后治疗组血小板计数明显高于对照组(P<0.05)。6个月后治疗组随访有效率(51.43%)明显优于对照组(28.57%)(P<0.05)。结论:紫茜合剂治疗慢性原发免疫性血小板减少症疗效确切,还可减少服用达那唑引起的不良反应,同时延长有效期。

Objective： To observe the efficacy of Ziqian compound for chronic primary immune thrombocytopenia. Methods： Totally 70 patients were randomized into a treatment group（ Ziqian compound ＋ danazol） and a control group（ danazol only）,with 35 in each group. The treatment lasted 6 months. The platelet count after treatment was observed in both groups. Results： The total effective rates of the treatment group and control group were 65. 71% and 48. 57% respectively,with a significant difference between two groups（ P 0. 05）.After treatment,the platelet count in the treatment group was significantly higher than that in the control group.After 6 months,the follow-up efficiencies of the treatment group and control group were 51. 43% and28. 57% respectively,with a significant difference between two groups（ P 0. 05）. Conclusion： Ziqian compound is effective for chronic primary immune thrombocytopenia,and it can reduce adverse reactions caused by application of danazol and extend the period in the meanwile.